AthleticsMD Clinical DeskSchedule an evaluation

Daily digest

What's trending, October 3, 2026

In the news

GLP-1 use associated with nail detachment, hair loss

Healio reports on a congress presentation of an observational study comparing 575 GLP-1 receptor agonist users with 1,329 non-users, all with type 2 diabetes and/or obesity. Users reported more nail disorders and hair loss, including nail detachment (39.3% vs. 8.7%) and new-onset hair loss (26.1% vs. 11.6%). Researchers say the design cannot establish that the drugs caused the changes; a prospective study is planned.

Why it matters: Relevant to adults with type 2 diabetes or obesity who use or are considering GLP-1 medicines, and to the clinicians and dermatologists involved in their care.

healio.com · October 3, 2026

Our summary →
In the news

New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells

Medical Xpress reports EASD meeting data on CBL-514, an experimental injection meant to make fat cells self-destruct. In a small phase 2 MRI subgroup, CBL-514 (n=23) versus placebo (n=17), with participants of BMI 22–30 kg/m2, visceral fat was 10.45% lower than baseline versus 11.76% higher on placebo. A developer scientist co-authored it. Less weight regain after stopping tirzepatide was seen only in rats; phase 3 is recruiting.

Why it matters: Relevant to Maryland adults weighing nonsurgical abdominal fat-reduction options and to clinicians who manage medical weight loss or refer patients for body contouring.

medicalxpress.com · October 3, 2026

Our summary →
In the news

Even one strength training session a week could make a difference

In a commentary republished by ScienceDaily from The Conversation, Newcastle University researcher Christopher Hurst argues that strength training is central to countering sarcopenia, the age-related loss of muscle mass and strength. He cites evidence that a single weekly session may bring meaningful strength gains, particularly for newcomers. He adds that lighter weights lifted for 20 to 25 repetitions can match heavier loads when effort is high.

Why it matters: Relevant to older adults concerned about age-related muscle loss, mobility or falls, and to the rehabilitation and primary care clinicians who refer them.

sciencedaily.com · October 3, 2026

Our summary →
In the news

Foundayo noninferior to insulin glargine for CV outcomes

Healio reports on ACHIEVE-4, a Lilly-funded trial in which 2,749 patients with type 2 diabetes, overweight or obesity and established cardiovascular or kidney disease received oral orforglipron (Foundayo) or insulin glargine. At a median 2 years, major cardiovascular events occurred in 4.2% versus 5%, meeting noninferiority. The trial was not powered for superiority. Hypoglycemia was less common with orforglipron, while GI adverse events were more common.

Why it matters: Relevant to Maryland adults with type 2 diabetes, excess weight and cardiovascular or kidney disease, and to the endocrinology and cardiology clinicians who care for them.

healio.com · October 3, 2026

Our summary →
In the news

Survodutide induces ‘impressive’ weight loss in type 2 diabetes

Healio reports results from the phase 3 SYNCHRONIZE-2 trial of survodutide, a once-weekly injectable GLP-1/glucagon dual agonist, in 752 adults with type 2 diabetes and overweight or obesity. At 76 weeks, weight fell 8.2% and 9.8% on the 3.6 mg and 6 mg doses versus 3.9% with placebo. Gastrointestinal side effects were common and led some participants to stop treatment. The trial was funded by Boehringer Ingelheim.

Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to the clinicians who refer them.

healio.com · October 3, 2026

Our summary →
In the news

Combining eloralintide with tirzepatide increases weight loss

Healio reports phase 2 trial data, presented at the European Association for the Study of Diabetes meeting, in 367 adults with type 2 diabetes and overweight or obesity. Over 48 weeks, the investigational amylin agonist eloralintide plus tirzepatide produced weight loss of up to 23.3%, versus 14.8% with tirzepatide 15 mg alone. Gastrointestinal side effects were most common. The Lilly-funded trial precedes a planned phase 3 study.

Why it matters: Relevant to Maryland adults with type 2 diabetes and overweight or obesity exploring medical weight loss, and to clinicians who refer them for metabolic care.

healio.com · October 3, 2026

Our summary →

AthleticsMD Clinical Desk

Today's front page

The newest articles and the day's news on GLP-1 & weight loss, Metabolic health, Hormones and more.

Go to the front page →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.

Schedule an evaluation →